- Cayman Chemical has partnered with Curapath to make PEG-free shielding lipids more widely available for lipid nanoparticle (LNP) research.
- The collaboration expands access to Curapath’s polysarcosine (pSar) and polyaminoacid-based lipids, offering alternatives to PEGylated lipids.
Cayman Chemical has entered into a partnership with Curapath to broaden access to PEG-free shielding lipids for lipid nanoparticles (LNPs). The collaboration aims to support researchers developing non-viral drug delivery systems, gene therapies, mRNA vaccines, and biologic treatments.
Through the agreement, Cayman will add Curapath’s proprietary polysarcosine (pSar) and polyaminoacid-based lipids to its catalogue. These materials, manufactured at Curapath’s site in Valencia, Spain, will be available in both research and GMP quality. Other polymers, including poly(lysine), poly(glutamic acid), and cationic polymers designed for gene transfection and delivery, will also be offered.
PEGylated lipids have traditionally been used to protect LNPs from immune system recognition. However, concerns over PEG-related immunogenicity and adverse reactions are prompting a shift toward safer alternatives. Curapath’s pSar lipids are described as non-toxic, non-immunogenic, biodegradable, and comparable in efficacy to PEGylated lipids.
Cayman’s extensive expertise in lipid chemistry, synthesis, and analysis underpins the collaboration. By working with Curapath, the company is expanding its offering of cutting-edge tools for LNP formulation.
“At Curapath, we’re proud to offer next-generation shielding lipids that address the growing need for safer, PEG-free alternatives in LNP formulation. This partnership with Cayman Chemical enables broader access to Curapath’s proprietary polymers, empowering researchers worldwide to develop more effective and biocompatible therapies,” the company stated.
